These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8231573)

  • 1. Differences in dendritic cells in congenital and acquired cholesteatomas.
    Frankel S; Berson S; Godwin T; Han JC; Parisier SC
    Laryngoscope; 1993 Nov; 103(11 Pt 1):1214-7. PubMed ID: 8231573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retraction pockets and attic cholesteatomas.
    Sadé J
    Acta Otorhinolaryngol Belg; 1980; 34(1):62-84. PubMed ID: 6162358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Congenital cholesteatoma of the middle ear in children].
    Charachon R; Gratacap B; Fillatre B
    Rev Laryngol Otol Rhinol (Bord); 1992; 113(1):7-10. PubMed ID: 1344514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral congenital middle ear cholesteatomas.
    Wang R; Zubick HH; Vernick DM; Strome M
    Laryngoscope; 1984 Nov; 94(11 Pt 1):1461-3. PubMed ID: 6492968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital cholesteatomas in children: an embryologic correlation.
    Levenson MJ; Michaels L; Parisier SC; Juarbe C
    Laryngoscope; 1988 Sep; 98(9):949-55. PubMed ID: 3412093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased numbers of mast cells in human middle ear cholesteatomas: implications for treatment.
    Albino AP; Reed JA; Bogdany JK; Sassoon J; Parisier SC
    Am J Otol; 1998 May; 19(3):266-72. PubMed ID: 9596172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesteatoma: a molecular and cellular puzzle.
    Albino AP; Kimmelman CP; Parisier SC
    Am J Otol; 1998 Jan; 19(1):7-19. PubMed ID: 9455941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congenital cholesteatomas of the middle ear in children: origin and management.
    Levenson MJ; Michaels L; Parisier SC
    Otolaryngol Clin North Am; 1989 Oct; 22(5):941-54. PubMed ID: 2694070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of congenital pediatric cholesteatomas.
    Parisier SC; Levenson MJ; Edelstein DR; Bindra GS; Han JC; Dolitsky JN
    Am J Otol; 1989 Mar; 10(2):121-3. PubMed ID: 2735383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Protein Expression in Congenital and Acquired Cholesteatomas.
    Shin SH; Huang M; Kim SH; Choi JY
    PLoS One; 2015; 10(9):e0137011. PubMed ID: 26335306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Otoendoscopy in cholesteatoma surgery of the middle ear: what benefits can be expected?
    Ayache S; Tramier B; Strunski V
    Otol Neurotol; 2008 Dec; 29(8):1085-90. PubMed ID: 18836388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune cell profile in invasive cholesteatomas: preliminary findings.
    Hussein MR; Sayed RH; Abu-Dief EE
    Exp Mol Pathol; 2010 Apr; 88(2):316-23. PubMed ID: 20045407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Congenital cholesteatomas in Japanese--forty from our experience and fifty-five from a survey of the Japanese literature].
    Suetake M; Kobayashi T; Sasaki N; Takasaka T; Yuasa R
    Nihon Jibiinkoka Gakkai Kaiho; 1996 Sep; 99(9):1200-7. PubMed ID: 8914417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma.
    Reichert TE; Scheuer C; Day R; Wagner W; Whiteside TL
    Cancer; 2001 Jun; 91(11):2136-47. PubMed ID: 11391595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration in cholesteatoma fibroblasts: induction of neoplastic-like phenotype.
    Parisier SC; Agresti CJ; Schwartz GK; Han JC; Albino AP
    Am J Otol; 1993 Mar; 14(2):126-30. PubMed ID: 8503484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p53 protein in human middle ear cholesteatomas: pathogenetic implications.
    Albino AP; Reed JA; Bogdany JK; Sassoon J; Desloge RB; Parisier SC
    Am J Otol; 1998 Jan; 19(1):30-6. PubMed ID: 9455944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated level of tenascin and matrix metalloproteinase 9 correlates with the bone destruction capacity of cholesteatomas.
    Juhász A; Sziklai I; Rákosy Z; Ecsedi S; Adány R; Balázs M
    Otol Neurotol; 2009 Jun; 30(4):559-65. PubMed ID: 19395987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible canal wall down mastoidectomy for acquired cholesteatomas: preliminary results.
    McElveen JT; Chung AT
    Laryngoscope; 2003 Jun; 113(6):1027-33. PubMed ID: 12782816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative analysis of the proliferative capacity of cholesteatomas].
    Bernal Sprekelsen M; Ebmeyer J; Buchbinder A; Sudhoff H
    Acta Otorrinolaringol Esp; 2000 May; 51(4):299-307. PubMed ID: 10984952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [DNA cytometric studies of cholesteatoma of the middle ear].
    Bollmann R; Knopp U; Tolsdorff P
    HNO; 1991 Aug; 39(8):313-4. PubMed ID: 1938497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.